kin in Medical Technology

Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases

...ivery device represents a paradigm shift in the way physicians will deliver drugs to all organ systems in the future. "The implantation of this kind of device on any organ and the ability to deliver medication to the affected organ, could be a huge advance in how we currently treat cancer," Dr. M...

Regular Yoga Practice Is Associated With Mindful Eating

...as a BMI within the normal range. Moving forward, Kristal and colleagues suggest that their Mindful Eating Questionnaire, the first tool of its kind to characterize and measure mindful eating, may be useful both in clinical practice and research to understand and promote healthy dietary behavior....

Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis

...l Trial The Phase 2 randomized, placebo- and comparator-controlled, parallel-group, dose-finding study was conducted in the U.S., Argentina, United kingdom, and India and was designed to evaluate the safety and efficacy of BA058 in the treatment of otherwise healthy postmenopausal women with osteopor...

Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

...cense agreement for the development and commercialisation of Debio 0930, a small molecule activator of AMPK (adenosine monophosphate activated protein kinase) for the treatment of diabetes and metabolic diseases. Activation of AMPK has been shown to lower fasting blood glucose levels and improve glucose...

Scientists Discover Origin of Malaria

...olfe's discovery of the origin of human malaria is a perfect example of the kind of research supported by the NIH Director's Pioneer Award program, which ...onally innovative and potentially paradigm-shifting ideas," said Raynard S. kington, M.D., Ph.D., acting director of the National Institutes of Health. ...

Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome

...A has a novel mechanism of action that inhibits a target enzyme called glutathione S- transferase P1-1 which in turn facilitates the activation of JNK kinase, a key regulator of cellular growth and differentiation of blood. TELINTRA has been shown to stimulate normal multilineage differentiation of blo...

John Legend and Gap Join (PRODUCT)RED(TM) to Help Eliminate AIDS in Africa with Exclusive (RED)ZONE Seating at Madison Square Garden

...vy, Piperlime and Athleta brand names. Fiscal 2008 sales were $14.5 billion. Gap Inc. operates more than 3,100 stores in the United States, the United kingdom, Canada, France, Japan and Ireland. In addition, Gap Inc. is expanding its international presence with franchise agreements in Asia, Europe, Lati...

Covance Receives Highest Level of Phase I Accreditation

...reditation was awarded to Covance's clinical research unit in Leeds, United kingdom, where the company conducts first-in-human studies, including trials r...n 500 beds across nine Phase I clinics located in the United States, United kingdom, and Switzerland. About Covance Covance, with headquart...

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

...ve where it ultimately causes inflammation in the joints and destroys soft tissues, cartilage and bone. Rigel's R788 is a novel, orally available syk kinase inhibitor designed to interrupt the cellular signaling at the trigger point of inflammation, thereby stopping the progression of the disease. In J...

Injection Reverses Heart-Attack Damage

...ErbB4, cardiomyocyte proliferation was further enhanced, demonstrating that NRG1 works by stimulating this receptor. They also identified the specific kinds of cardiomyocytes (mononucleated) that are most likely to respond to treatment. In 2007, Kuhn and colleagues first demonstrated that the ...

July 2009 Mayo Clinic Health Letter Highlights a Positive Outlook, Bell's Palsy and Heart Valve Repair

... outlook. Options might be consciously looking for the good in life, being grateful, looking for pleasure in small things or practicing random acts of kindness. Other people may need treatment from a mental health professional to help shift to a more positive perspective. Bell's Palsy: F...

Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler

...rovide the support the skin needs for long lasting natural feeling results. This is different from temporary dermal fillers that are made of different kinds of natural or synthetic materials that are completely absorbed by the body over time and require repeat injections to maintain wrinkle correction. ...

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations

...ns and signed license agreements for the distribution of Salvacyl(R)/Moapar(R) in nine major European countries, including France, Germany, the United kingdom, Sweden, Norway, Denmark, Belgium, the Netherlands and Finland. The product was launched earlier this year in Germany and Belgium. Initial contac...

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations

...ns and signed license agreements for the distribution of Salvacyl(R)/Moapar(R) in nine major European countries, including France, Germany, the United kingdom, Sweden, Norway, Denmark, Belgium, the Netherlands and Finland. The product was launched earlier this year in Germany and Belgium. Initial contac...

Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364

... kinG OF PRUSSIA, Pa., July 20 /PRNewswire/ -- Cytokine PharmaSciences, Inc. to...-inflammatory and autoimmune therapeutics. The Company is headquartered in king of Prussia (near Philadelphia), Pennsylvania. A wholly owned subsidiary, ...

Lupus Research Institute Highly Encouraged by Benlysta(TM) Trial Results

... North America and Europe. BLISS-52 and BLISS-76 are the largest clinical trials ever conducted in people with lupus. First of its kind "Benlysta(TM) is the first 'targeted biological agent' developed specifically for systemic lupus that has the potential to obtain FDA app...

Michael J. Fox Foundation Awards Over $2 Million for Validation of 10 Parkinson's Therapeutic Targets

... Smo1 a ntagonists to boost endogenous GDNF expression in the adult striatum Andreas H. Kottman, PhD, Columbia University Polo-like kinases as therapeutic targets for Parkinson ' s disease Hilal A. Lashuel, PhD, and Patrick Aebischer, MD, Ecole Polytechnique Federale de Lausann...

Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

...ve where it ultimately causes inflammation in the joints and destroys soft tissues, cartilage and bone. Rigel's R788 is a novel, orally available syk kinase inhibitor designed to interrupt the cellular signaling at the trigger point of inflammation, thereby stopping the progression of the disease. ...

New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects

...ntities (NMEs) in the drug development pipeline comprise various classes of kinase inhibitors that cause unacceptable toxicity in humans. Proper formulati...er, currently, no appropriate formulation technology is available for these kinase inhibitors. This project focuses on a systematic approach in whi...

Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)

... Acura Pharmaceuticals, Inc. (Nasdaq: ACUR ) and king Pharmaceuticals, Inc. (NYSE: KG ) announced to... abuse deterrent benefits of Acurox(R). Acura and king are currently evaluating the FDA's Complete Resp...innovative abuse deterrent technologies. Acura and king jointly developed Acurox(R) Tablets and are deve...

deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia

...ics, the National-University Hospital in Reykjavik, the University of Aberdeen , the Ravenscraig Hospital in Greenock, the Institute of Psychiatry at king's College London, the National Public Health Institute in Helsinki, the Ludwig Maximilians University and GlaxoSmithKline's Genetic Research Center ...

Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia

...putting the number of BPH/nocturia sufferers at 55 million in the seven largest markets world wide, and only 10% of these believed to be receiving any kind of treatment, it is a clear area of unmet medical need estimated to be worth in excess of $500m. The hormone vasopressin is involved in the regulati...

Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)

...orway, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Spain (co-promotion with BIAL from launch) Sweden, Switzerland, Turkey, Ukraine and United kingdom. About epilepsy, partial-onset seizures and their treatment Epilepsy is one of the most common neurological diseases, affecting app...

SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts

...th Sports Institute and experts in psychiatry, substance abuse, toxicology, kinesiology, clinical psychology, and sports medicine will be making presentat...iversity , Syracuse, NY Phil Buckenmeyer, PhD Chair, Department of kinesiology, SUNY Cortland , Cortland, NY Mary Claire O'Brien, MD As...

King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use

...Meeting RENO, Nev., June 25 /PRNewswire/ -- king Pharmaceuticals, Inc. (NYSE: KG ) today announ...ng of the College on Problems of Drug Dependence. king is also developing other pain medicines employin... pain," said Eric Carter, Chief Science Officer of king Pharmaceuticals. "Our expectation is that these ...

Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis

...mp;rank=2 "Our recent preclinical studies suggest that CTS-1027 treatment has the potential to impact the second phase of HCV virus inhibitory kinetics in patients. This phase is associated with the gradual reduction and replacement of HCV infected cells by uninfected liver cells. Interestingly,...

Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries

...astrations, as well as to other types of medication." Salvacyl(R) is registered in seven other European countries, including France, the United kingdom, Sweden, Norway, Denmark, the Netherlands and Finland, and will be launched progressively by Debiopharm's commercial partners in the course of 20...

Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia

...Cephalon scientists, lestaurtinib is a potent inhibitor of several tyrosine kinases including FLT3 and a Janus kinase (JAK2). In leukemic cells, lestaurtinib inhibits FLT3 activity and indu...

Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program

...me laboratory research with direct mentoring from internationally-recognized scientists. Roskamp is an Affiliated Research Centre (ARC) of the United kingdom's Open University (OU) and was recently granted a license from the Commission for Independent Education within the Florida Department of Educatio...

Scottsdale Facility to Be First in U.S. to Showcase True REST Technology

... will open a True REST Float Center in Scottsdale, Ariz. - the first of its kind in the U.S. In the United kingdom, more than 300 of these types of centers are in operation, with hundre...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

...thwest) where certain fungal infections like histoplasmosis or coccidioidomycosis are common. You should not start SIMPONI(TM) if you have any kind of infection. Tell your doctor if you are prone to or have a history of infections or have diabetes. You should also tell your doctor if you are c...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

...thwest) where certain fungal infections like histoplasmosis or coccidioidomycosis are common. You should not start SIMPONI(TM) if you have any kind of infection. Tell your doctor if you are prone to or have a history of infections or have diabetes. You should also tell your doctor if you are c...

Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines

...ormin and sulfonylurea in the ADOPT study. Although RECORD was not designed to study microvascular endpoints, previous studies such as the United kingdom Prospective Diabetes Study, which studied other medicines, have found that improved glycaemic control may reduce complications of diabetes that c...

Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials

...e are gratified at the level of interest the bavituximab program is now receiving from leading cancer researchers and drug developers," said Steven W. king, president and CEO of Peregrine. "We believe this growing interest reflects our recent progress in successfully advancing all three Phase II bavitu...

New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease

...ission through one year." The SONIC clinical trial is the first of its kind to compare REMICADE, an anti-tumor necrosis factor (TNF)-alpha therapy, w... their doctors about any medications they are taking, including vaccines or kineret (anakinra), and if a woman is pregnant, plans to become pregnant or is...

Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients

...ation of clinical data for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, at the American Society ...MDLOGO ) ENMD-2076, a small molecule, oral kinase inhibitor that targets Aurora A and other kin ases critical to angiogenesis, cellular growth and...

Back to Normal: Surgery Improves Outcomes for Spine Patients

...ed disability, as well as the most expensive in terms of workers compensation and medical costs. Degenerative spondylolisthesis is one example of this kind of painful back condition. "Degenerative spine disease can be a debilitating condition. When well informed, surgery is a good treatment choice,...

Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients

...ted through the PI3K/PTEN pathway. About PI3 kinase Phosphatidylinositol 3 kinases (PI3K) are involved in one of the major pathw... and survival/apoptosis. Dysregulation of the PI3 kinase signaling cascades can lead to cancer and aber...

Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506

...targeted VEGFR2-TIE2 anti-angiogenic oral tyrosine kinase inhibitor (TKI) with a kinase inhibition profile targeting angiogenic, stromal and oncogenic receptor tyrosine kinases (TK). In preclinical studies, BAY 73-4506 ha...

New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer

...ing in Orlando, Florida, from May 29 to June 2, 2009. Neratinib is an investigational orally administered irreversible inhibitor of the HER-2 and EGFR kinases. "The data gathered from these studies provide additional evidence suggesting that neratinib, when combined with these therapies, is an act...